# Gemcitabine Hydrochloride, Cisplatin, and AGS-003-BLD in Treating Patients With Muscle-Invasive Bladder Cancer Undergoing Surgery

Source: https://onco.cc/trials/nct02944357/  
OnCo record `nct02944357` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

An trial of Rocapuldencel-T run by Mayo Clinic, withdrawn before enrolling.

## Summary

Gemcitabine Hydrochloride, Cisplatin, and AGS-003-BLD in Treating Patients With Muscle-Invasive Bladder Cancer Undergoing Surgery is an interventional study registered as NCT02944357 by Mayo Clinic, started 2016-11. Conditions recorded: Infiltrating Bladder Urothelial Carcinoma, Stage II Bladder Urothelial Carcinoma, Stage III Bladder Urothelial Carcinoma and Stage IV Bladder Urothelial Carcinoma. Interventions recorded: Cisplatin, Gemcitabine Hydrochloride, Radical Cystectomy and Tumor Cell-Derived Vaccine Therapy.

## Fields

- Kind: Trial
- Status: withdrawn
- Last checked: 2026-11-03
- Tags: pipeline; ctgov-ingest
- Registry id: NCT02944357
- Phase: not-applicable
- Setting: Pilot Study of Gemcitabine and Cisplatin Plus AGS-003-BLD in Patients With Muscle-Invasive Bladder Cancer Undergoing Neoadjuvant Cisplatin-Based Chemotherapy
- Sponsor: Mayo Clinic

## Sources

- ClinicalTrials.gov NCT02944357: https://clinicaltrials.gov/study/NCT02944357

## Connected records

- cancers: [Bladder & urothelial cancer](https://onco.cc/cancers/urothelial/)
- drugs: [Rocapuldencel-T](https://onco.cc/drugs/rocapuldencel-t/)
- companies: [Argos Therapeutics](https://onco.cc/companies/argos-therapeutics/)

---
JSON: https://onco.cc/api/v1/entities/nct02944357.json